| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| ONL-1204 | ONL-1204 | Phase 2 Clinical | Onl Therapeutics | Glaucoma, Open-Angle; Retinal Detachment; Geographic Atrophy | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Kanglaite | Approved | Zhejiang Kanglaite Pharmaceutical Co Ltd | Kanglaite | Mainland China | Liver Neoplasms; Carcinoma, Non-Small-Cell Lung | Zhejiang Kanglaite Pharmaceutical Co Ltd | 1997-01-01 | Liver Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



